{{Rsnum
|rsid=2279343
|Gene=CYP2B6
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Orientation=plus
|Orientation=plus
|Chromosome=19
|position=41009358
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|Gene_s=CYP2B6
}}[[rs2279343]], also known as Lys262Arg, is a SNP within the [[CYP2B6]] gene.

{{PMID|12642465}} variants including the Arg allele include CYP2B6*4, CYP2B6*6, and CYP2B6*7

{{PharmGKB
|RSID=rs2279343
|Name_s=CYP2B6*4, CYP2B6:785A>G
|Gene_s=CYP2B6, CYP2A7P1
|Feature=Exon/NonSyn, NA
|Evidence=PubMed ID:19005482
|Annotation=Risk or phenotype-associated allele: G. Phenotype: CYP2B6*4 genotype in the transplant recipient was associated with oral mucositis. Study size:107 . Study population/ethnicity: Donors and patients with leukemia after HLA-identical hematopoietic stem cell transplantation, France. Significance metric(s): p = 0.0067. Type of association: TOX
|Drugs=cyclophosphamide
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165282247
}}

{{PharmGKB
|RSID=rs2279343
|Name_s=CYP2B6:K262R, CYP2B6:18053A>G, CYP2B6*4, part of CYP2B6*6
|Gene_s=CYP2B6, CYP2A7P1
|Feature=Exon/NonSyn, NA
|Evidence=PubMed ID:14515060; PubMed ID:17015050; PubMed ID:18695978
|Annotation=The CYP2B6*4 allele has been associated with increased activity against both nicotine and bupropion substrates.
|Drugs=bupropion; nicotine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA162565796
}}

{{PharmGKB
|RSID=rs2279343
|Name_s=CYP2B6:785A>G; CYP2B6:Lys262Arg; CYP2B6*4
|Gene_s=CYP2B6, CYP2A7P1
|Feature=Exon/NonSyn, NA
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/cyp2b6/variant.jsp
|Annotation=This variant is found alone as the CYP2B6*4 allele and also in combination as part of several other haplotypes. It has higher expression levels than other variants but its phenotype with respect to drugs is unclear. See VIP annotation for more details.
|Drugs=bupropion
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA164891493
}}

{{PMID Auto
|PMID=21790905
|Title=CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction
}}

{{PMID Auto
|PMID=21886015
|Title=Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles
}}

{{PMID|18728241|OA=1
}} Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.

{{PMID|19076156|OA=1
}} Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

{{PMID|19239339|OA=1
}} Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.

{{PMID|19659438|OA=1
}} CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.

{{PMID|20459744|OA=1
}} Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.

{{PMID|21694616}} CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer.

{{PMID Auto
|PMID=23249875
|Title=Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels:  a CYP2B6 gene resequencing study
}}

{{PMID Auto
|PMID=24260284
|Title=CYP2B6 Non-Coding Variation Associated with Smoking Cessation Is Also Associated with Differences in Allelic Expression, Splicing, and Nicotine Metabolism Independent of Common Amino-Acid Changes
|OA=1
}}

{{PMID Auto
|PMID=23104099
|Title=Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.
|OA=1
}}

{{PMID Auto
|PMID=23133420
|Title=Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin.
|OA=1
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}